课题基金 / 基金详情

Viral and cellular factors affecting early steps in HIV reverse transcription

Viral and cellular factors affecting early steps in HIV reverse transcription
影响 HIV 逆转录早期步骤的病毒和细胞因素
批准号:
nhmrc : 298926
负责人:
A/Pr David Harrich
金额:
$31.06万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2004
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2004-01-01 至 2006-12-31

项目摘要

项目成果

A/Pr David Harrich的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
One of the key events in the life cycle of HIV is the conversion of viral RNA into a double stranded DNA intermediate. This process, called reverse transcription, is carried out by the viral enzyme reverse transcriptase (RT) in conjunction with other viral and cellular factors. While HIV RT has been extensively studied and RT inhibitors have been used in anti-retroviral therapy for HIV patients, other viral and cellular factors essential for efficient HIV reverse transcription have not been properly investigated and may represent a new class of anti-HIV targets.This project, based on our long standing (>10 years) research interest and experience, aims at identification of the viral and cellular factors particularly involved in the early steps of HIV reverse transcription.We have obtained preliminary data which lead to hypotheses regarding what kind of viral and cellular factors might be involved and their possible modes of action. Experiments have been designed to specifically prove or disprove these hypotheses. Thus this project will help us achieve a more comprehensive understanding on how HIV uses other viral and cellular factors, in addition to RT, to accomplish one of the mandatory stage of its growth (reverse transcription); and identify viral and cellular factors which can be further explored as new targets for anti-retroviral therapy. This is particularly important, as HIV resistance to current drug therapy has emerged as one serious issue facing HIV patients, and the HIV care communities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A potent anti-HIV-1 gene therapy agent in a humanised mouse model
A potent anti-HIV-1 gene therapy agent in a humanised mouse model
  • 批准号:
    nhmrc : GNT1085359
  • 项目类别:
    Project Grants
  • 资助金额:
    $110.11万
  • 财政年份:
    2015
  • 负责人:
    A/Pr David Harrich
  • 依托单位:
eEF1A1 is critical for HIV-1 reverse transcription and replication
The Human Eukaryotic Translation Elongation Factor 1A is a Paramyxovirus Virus Dependency Factor
国内基金
海外基金
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    汪雪玲
  • 依托单位:
长寿基因SIRT7调控核苷酸切除修复通路的机制研究
  • 批准号:
    32100605
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    耿安珂
  • 依托单位:
溶酶体蛋白LAPTM4B通过与Xc-系统相互作用调控谷胱甘肽代谢的机制研究
  • 批准号:
    32100623
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    周可成
  • 依托单位:
小鼠肺分支早期发育中肺上皮单细胞的时-空转录组的建立与分析